PDP1 and acute myeloid leukemia: AML#3 and AML#18 were low in PDK1 expression (Fig. 5d), low in PDK1 activity based on P-PDH Ser293 levels (Fig. 5f), low in basal glycolytic activity (Fig. 5g) and these AMLs were less sensitive to DAP (Fig. 5c).